Replies to post #676667 on NorthWest Biotherapeutics Inc (NWBO)

[georgebailey]

BP are competitors so their “database of antigens” aren’t available to license. Academic institutions would be.

[beartrap12]

jimmy, I think you hit it on the head.

BP maximizes money and therefore could be incentivized to delay or bury innovations that threaten status quo money makers.

Also, I think NWBO management knows exactly what they need to enrich and improve our DCVax platform. BP doesn't have a clue. They are building their cancer platforms around products like Keytruda that don't necessarily cure, but extends life, or only work on cancers that are easier to extend life. Meeanwhile, NWBO wants to "CURE" cancer. This is why Dr. Liau was added to our scientific board. She led the research on DCVax and knows what likely helps improve our product and I would not be surprised if she is guiding NWBO management to in-license certain research, (perhaps from UCLA?) along with Dr. Bosch, who guided DCVax to be a position where it could become a commercial product.

I look forward to hearing more about these academia research patents we've added to our arsenal. I'm sorry they didn't tell us the whole story in yesterday's 10K, but perhaps they are holding back info from competitors(?)